PURPOSE: The purpose of this study was to evaluate the prevalence of cardiac autonomic neuropathy (CAN) in a cohort of patients with type 2 diabetes, truly asymptomatic for coronary artery disease (CAD), using heart rate variability (HRV) and (123)I-metaiodobenzylguanidine ((123)I-mIBG) myocardial scintigraphy. METHODS: The study group comprised 88 patients with type 2 diabetes prospectively recruited from an outpatient diabetes clinic. In all patients myocardial perfusion scintigraphy, CAN by HRV and (123)I-mIBG myocardial scintigraphy were performed. Two or more abnormal tests were defined as CAN-positive (ECG-based CAN) and one or fewer as CAN-negative. CAN assessed by (123)I-mIBG scintigraphy was defined as abnormal if the heart-to-mediastinum ratio was <1.8, the washout rate was >25%, or the total defect score was >13. RESULTS: The prevalence of CAN in patients asymptomatic for CAD with type 2 diabetes and normal myocardial perfusion assessed by HRV and (123)I-mIBG scintigraphy was respectively, 27% and 58%. Furthermore, in almost half of patients with normal HRV, (123)I-mIBG scintigraphy showed CAN. CONCLUSION: The current study revealed a high prevalence of CAN in patients with type 2 diabetes. Secondly, disagreement between HRV and (123)I-mIBG scintigraphy for the assessment of CAN was observed.
PURPOSE: The purpose of this study was to evaluate the prevalence of cardiac autonomic neuropathy (CAN) in a cohort of patients with type 2 diabetes, truly asymptomatic for coronary artery disease (CAD), using heart rate variability (HRV) and (123)I-metaiodobenzylguanidine ((123)I-mIBG) myocardial scintigraphy. METHODS: The study group comprised 88 patients with type 2 diabetes prospectively recruited from an outpatientdiabetes clinic. In all patients myocardial perfusion scintigraphy, CAN by HRV and (123)I-mIBG myocardial scintigraphy were performed. Two or more abnormal tests were defined as CAN-positive (ECG-based CAN) and one or fewer as CAN-negative. CAN assessed by (123)I-mIBG scintigraphy was defined as abnormal if the heart-to-mediastinum ratio was <1.8, the washout rate was >25%, or the total defect score was >13. RESULTS: The prevalence of CAN in patients asymptomatic for CAD with type 2 diabetes and normal myocardial perfusion assessed by HRV and (123)I-mIBG scintigraphy was respectively, 27% and 58%. Furthermore, in almost half of patients with normal HRV, (123)I-mIBG scintigraphy showed CAN. CONCLUSION: The current study revealed a high prevalence of CAN in patients with type 2 diabetes. Secondly, disagreement between HRV and (123)I-mIBG scintigraphy for the assessment of CAN was observed.
Authors: F Anan; N Takahashi; T Shinohara; M Nakagawa; T Masaki; I Katsuragi; K Tanaka; T Kakuma; H Yonemochi; N Eshima; T Saikawa; H Yoshimatsu Journal: Eur J Clin Invest Date: 2006-07 Impact factor: 4.686
Authors: N Hattori; N Tamaki; T Hayashi; I Masuda; T Kudoh; M Tateno; E Tadamura; Y Yonekura; K Nakao; J Konishi Journal: J Nucl Med Date: 1996-12 Impact factor: 10.057
Authors: Frans J Th Wackers; Lawrence H Young; Silvio E Inzucchi; Deborah A Chyun; Janice A Davey; Eugene J Barrett; Raymond Taillefer; Steven D Wittlin; Gary V Heller; Neil Filipchuk; Samuel Engel; Robert E Ratner; Ami E Iskandrian Journal: Diabetes Care Date: 2004-08 Impact factor: 19.112
Authors: Omar Asghar; Parthiban Arumugam; Ian Armstrong; Simon Ray; Matthias Schmitt; Rayaz A Malik Journal: Nucl Med Commun Date: 2017-01 Impact factor: 1.690
Authors: Jan van Ramshorst; Saskia L M A Beeres; Sander F Rodrigo; Petra Dibbets-Schneider; Arthur J Scholte; Willem E Fibbe; Jaap J Zwaginga; Martin J Schalij; Jeroen J Bax; Douwe E Atsma Journal: Int J Cardiovasc Imaging Date: 2014-01-31 Impact factor: 2.357
Authors: Ming Yu; Jody Bozek; Melanie Lamoy; Mikhail Kagan; Pedro Benites; David Onthank; Simon P Robinson Journal: Eur J Nucl Med Mol Imaging Date: 2012-08-04 Impact factor: 9.236
Authors: Wooyoung Jang; Joong-Seok Kim; Jin Whan Cho; Jin Young Ahn; Yun Young Choi; Hee-Tae Kim Journal: Clin Auton Res Date: 2013-07-11 Impact factor: 4.435